Biotech

All Articles

Ascendis' dwarfism drug hits in stage 3, intimidates BioMarin

.Ascendis Pharma has emerged as a possible hazard to BioMarin's Voxzogo, reporting period 3 developm...

Despite ph. 3 skip, Alkeus finds road ahead of time for eye health condition asset

.Though Alkeus Pharmaceuticals' dental eye illness property fell short to significantly decrease geo...

Kairos goes social with $6M IPO to money trials of cancer cells drug

.Along with a triad of biotechs hitting the Nasdaq on Friday, it was actually effortless to overlook...

Vaccine as well as Keytruda combination efficient in squamous tissue carcinoma

.Invulnerable checkpoint inhibitors are actually the superheroes of cancer therapy. Medications like...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of significant management hirings, firings as...

Regeneron's Opdualag rival presents 57% response rate

.Regeneron is back with long-term follow-up for its own LAG-3 prevention and PD-1 inhibitor combo in...

AstraZeneca blog posts information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early examine the efficiency of its internal antibody-drug conjuga...

iTeos- GSK's TIGIT celebrity shows relevant remodeling

.After declaring a period 3 launch based upon good midstage results, iTeos and GSK are lastly sharin...

More joint FDA may accelerate unusual condition R&ampD: document

.The FDA should be even more open as well as collaborative to let loose a surge in approvals of unus...

Zenas, MBX, Bicara scalp to Nasdaq in hot day for biotech IPOs

.It's an extraordinarily occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and also ...